nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—SLC47A1—Mitoxantrone—multiple sclerosis	0.241	0.44	CbGbCtD
Sirolimus—SLCO1B1—Methotrexate—multiple sclerosis	0.0289	0.0527	CbGbCtD
Sirolimus—ABCB1—Methylprednisolone—multiple sclerosis	0.0272	0.0496	CbGbCtD
Sirolimus—CYP3A4—Fingolimod—multiple sclerosis	0.0253	0.0462	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0211	0.0385	CbGbCtD
Sirolimus—CYP3A7—Dexamethasone—multiple sclerosis	0.0211	0.0385	CbGbCtD
Sirolimus—ABCB1—Mitoxantrone—multiple sclerosis	0.0199	0.0362	CbGbCtD
Sirolimus—ABCB1—Betamethasone—multiple sclerosis	0.0177	0.0323	CbGbCtD
Sirolimus—ABCB1—Prednisolone—multiple sclerosis	0.0175	0.0318	CbGbCtD
Sirolimus—ABCB1—Prednisone—multiple sclerosis	0.0165	0.0301	CbGbCtD
Sirolimus—CYP3A4—Methylprednisolone—multiple sclerosis	0.0163	0.0297	CbGbCtD
Sirolimus—CYP3A5—Dexamethasone—multiple sclerosis	0.0158	0.0288	CbGbCtD
Sirolimus—CYP3A4—Triamcinolone—multiple sclerosis	0.0124	0.0225	CbGbCtD
Sirolimus—CYP3A4—Mitoxantrone—multiple sclerosis	0.0119	0.0217	CbGbCtD
Sirolimus—CYP3A4—Betamethasone—multiple sclerosis	0.0106	0.0193	CbGbCtD
Sirolimus—CYP3A4—Prednisolone—multiple sclerosis	0.0105	0.0191	CbGbCtD
Sirolimus—ABCB1—Dexamethasone—multiple sclerosis	0.0103	0.0188	CbGbCtD
Sirolimus—CYP3A4—Prednisone—multiple sclerosis	0.00989	0.018	CbGbCtD
Sirolimus—ABCB1—Methotrexate—multiple sclerosis	0.00828	0.0151	CbGbCtD
Sirolimus—MTOR—leg—multiple sclerosis	0.00744	0.165	CbGeAlD
Sirolimus—CYP3A4—Dexamethasone—multiple sclerosis	0.00617	0.0112	CbGbCtD
Sirolimus—EIF4E—nervous system—multiple sclerosis	0.00235	0.0522	CbGeAlD
Sirolimus—EIF4E—central nervous system—multiple sclerosis	0.00226	0.0503	CbGeAlD
Sirolimus—FGF2—medulla oblongata—multiple sclerosis	0.00191	0.0424	CbGeAlD
Sirolimus—EIF4E—brain—multiple sclerosis	0.0018	0.0399	CbGeAlD
Sirolimus—FGF2—midbrain—multiple sclerosis	0.00174	0.0387	CbGeAlD
Sirolimus—MTOR—brainstem—multiple sclerosis	0.00173	0.0386	CbGeAlD
Sirolimus—FGF2—spinal cord—multiple sclerosis	0.0017	0.0378	CbGeAlD
Sirolimus—MTOR—retina—multiple sclerosis	0.00167	0.0372	CbGeAlD
Sirolimus—FKBP1A—retina—multiple sclerosis	0.0015	0.0335	CbGeAlD
Sirolimus—FGF2—cerebellum—multiple sclerosis	0.00135	0.03	CbGeAlD
Sirolimus—SLC47A1—brainstem—multiple sclerosis	0.00134	0.0298	CbGeAlD
Sirolimus—FGF2—brain—multiple sclerosis	0.00109	0.0243	CbGeAlD
Sirolimus—FKBP1A—medulla oblongata—multiple sclerosis	0.00109	0.0242	CbGeAlD
Sirolimus—MTOR—spinal cord—multiple sclerosis	0.00108	0.024	CbGeAlD
Sirolimus—FKBP1A—midbrain—multiple sclerosis	0.000994	0.0221	CbGeAlD
Sirolimus—FKBP1A—spinal cord—multiple sclerosis	0.00097	0.0216	CbGeAlD
Sirolimus—SLC47A1—medulla oblongata—multiple sclerosis	0.000935	0.0208	CbGeAlD
Sirolimus—MTOR—nervous system—multiple sclerosis	0.000909	0.0202	CbGeAlD
Sirolimus—MTOR—central nervous system—multiple sclerosis	0.000875	0.0195	CbGeAlD
Sirolimus—MTOR—cerebellum—multiple sclerosis	0.000855	0.019	CbGeAlD
Sirolimus—SLC47A1—spinal cord—multiple sclerosis	0.000834	0.0185	CbGeAlD
Sirolimus—FKBP1A—nervous system—multiple sclerosis	0.000817	0.0182	CbGeAlD
Sirolimus—FKBP1A—central nervous system—multiple sclerosis	0.000787	0.0175	CbGeAlD
Sirolimus—FKBP1A—cerebellum—multiple sclerosis	0.000769	0.0171	CbGeAlD
Sirolimus—SLC47A1—nervous system—multiple sclerosis	0.000702	0.0156	CbGeAlD
Sirolimus—MTOR—brain—multiple sclerosis	0.000695	0.0154	CbGeAlD
Sirolimus—SLC47A1—central nervous system—multiple sclerosis	0.000676	0.015	CbGeAlD
Sirolimus—SLC47A1—cerebellum—multiple sclerosis	0.000661	0.0147	CbGeAlD
Sirolimus—FKBP1A—brain—multiple sclerosis	0.000625	0.0139	CbGeAlD
Sirolimus—SLC47A1—brain—multiple sclerosis	0.000537	0.0119	CbGeAlD
Sirolimus—ABCB1—retina—multiple sclerosis	0.000348	0.00774	CbGeAlD
Sirolimus—CYP3A4—nervous system—multiple sclerosis	0.000267	0.00594	CbGeAlD
Sirolimus—CYP3A4—central nervous system—multiple sclerosis	0.000257	0.00572	CbGeAlD
Sirolimus—ABCB1—medulla oblongata—multiple sclerosis	0.000252	0.0056	CbGeAlD
Sirolimus—ABCB1—midbrain—multiple sclerosis	0.00023	0.00511	CbGeAlD
Sirolimus—ABCB1—spinal cord—multiple sclerosis	0.000224	0.00499	CbGeAlD
Sirolimus—ABCB1—nervous system—multiple sclerosis	0.000189	0.0042	CbGeAlD
Sirolimus—ABCB1—central nervous system—multiple sclerosis	0.000182	0.00405	CbGeAlD
Sirolimus—ABCB1—cerebellum—multiple sclerosis	0.000178	0.00396	CbGeAlD
Sirolimus—ABCB1—brain—multiple sclerosis	0.000144	0.00321	CbGeAlD
Sirolimus—Angioedema—Betamethasone—multiple sclerosis	0.000101	0.000422	CcSEcCtD
Sirolimus—Stomatitis—Methotrexate—multiple sclerosis	9.99e-05	0.000419	CcSEcCtD
Sirolimus—Angiopathy—Prednisone—multiple sclerosis	9.98e-05	0.000419	CcSEcCtD
Sirolimus—Conjunctivitis—Methotrexate—multiple sclerosis	9.96e-05	0.000418	CcSEcCtD
Sirolimus—Confusional state—Methylprednisolone—multiple sclerosis	9.95e-05	0.000418	CcSEcCtD
Sirolimus—Immune system disorder—Prednisone—multiple sclerosis	9.94e-05	0.000417	CcSEcCtD
Sirolimus—Malaise—Dexamethasone—multiple sclerosis	9.92e-05	0.000416	CcSEcCtD
Sirolimus—Malaise—Betamethasone—multiple sclerosis	9.92e-05	0.000416	CcSEcCtD
Sirolimus—Oedema—Triamcinolone—multiple sclerosis	9.89e-05	0.000415	CcSEcCtD
Sirolimus—Anaphylactic shock—Triamcinolone—multiple sclerosis	9.89e-05	0.000415	CcSEcCtD
Sirolimus—Anaphylactic shock—Methylprednisolone—multiple sclerosis	9.87e-05	0.000414	CcSEcCtD
Sirolimus—Syncope—Betamethasone—multiple sclerosis	9.86e-05	0.000414	CcSEcCtD
Sirolimus—Syncope—Dexamethasone—multiple sclerosis	9.86e-05	0.000414	CcSEcCtD
Sirolimus—Infection—Triamcinolone—multiple sclerosis	9.83e-05	0.000412	CcSEcCtD
Sirolimus—Sweating—Methotrexate—multiple sclerosis	9.82e-05	0.000412	CcSEcCtD
Sirolimus—Infection—Methylprednisolone—multiple sclerosis	9.81e-05	0.000412	CcSEcCtD
Sirolimus—Haematuria—Methotrexate—multiple sclerosis	9.77e-05	0.00041	CcSEcCtD
Sirolimus—Shock—Triamcinolone—multiple sclerosis	9.73e-05	0.000408	CcSEcCtD
Sirolimus—Insomnia—Prednisolone—multiple sclerosis	9.73e-05	0.000408	CcSEcCtD
Sirolimus—Shock—Methylprednisolone—multiple sclerosis	9.71e-05	0.000408	CcSEcCtD
Sirolimus—Hepatobiliary disease—Methotrexate—multiple sclerosis	9.69e-05	0.000407	CcSEcCtD
Sirolimus—Nervous system disorder—Methylprednisolone—multiple sclerosis	9.68e-05	0.000406	CcSEcCtD
Sirolimus—Loss of consciousness—Dexamethasone—multiple sclerosis	9.67e-05	0.000406	CcSEcCtD
Sirolimus—Loss of consciousness—Betamethasone—multiple sclerosis	9.67e-05	0.000406	CcSEcCtD
Sirolimus—Epistaxis—Methotrexate—multiple sclerosis	9.66e-05	0.000405	CcSEcCtD
Sirolimus—Hypersensitivity—Mitoxantrone—multiple sclerosis	9.66e-05	0.000405	CcSEcCtD
Sirolimus—Paraesthesia—Prednisolone—multiple sclerosis	9.66e-05	0.000405	CcSEcCtD
Sirolimus—Tachycardia—Triamcinolone—multiple sclerosis	9.66e-05	0.000405	CcSEcCtD
Sirolimus—Nausea—Azathioprine—multiple sclerosis	9.64e-05	0.000404	CcSEcCtD
Sirolimus—Tachycardia—Methylprednisolone—multiple sclerosis	9.64e-05	0.000404	CcSEcCtD
Sirolimus—Skin disorder—Methylprednisolone—multiple sclerosis	9.59e-05	0.000402	CcSEcCtD
Sirolimus—Malnutrition—Prednisone—multiple sclerosis	9.58e-05	0.000402	CcSEcCtD
Sirolimus—Hyperhidrosis—Triamcinolone—multiple sclerosis	9.57e-05	0.000401	CcSEcCtD
Sirolimus—Hyperhidrosis—Methylprednisolone—multiple sclerosis	9.54e-05	0.0004	CcSEcCtD
Sirolimus—Hypertension—Dexamethasone—multiple sclerosis	9.5e-05	0.000399	CcSEcCtD
Sirolimus—Hypertension—Betamethasone—multiple sclerosis	9.5e-05	0.000399	CcSEcCtD
Sirolimus—Asthenia—Mitoxantrone—multiple sclerosis	9.41e-05	0.000395	CcSEcCtD
Sirolimus—Myalgia—Betamethasone—multiple sclerosis	9.37e-05	0.000393	CcSEcCtD
Sirolimus—Myalgia—Dexamethasone—multiple sclerosis	9.37e-05	0.000393	CcSEcCtD
Sirolimus—Anxiety—Dexamethasone—multiple sclerosis	9.33e-05	0.000392	CcSEcCtD
Sirolimus—Anxiety—Betamethasone—multiple sclerosis	9.33e-05	0.000392	CcSEcCtD
Sirolimus—Discomfort—Betamethasone—multiple sclerosis	9.25e-05	0.000388	CcSEcCtD
Sirolimus—Discomfort—Dexamethasone—multiple sclerosis	9.25e-05	0.000388	CcSEcCtD
Sirolimus—Haemoglobin—Methotrexate—multiple sclerosis	9.24e-05	0.000388	CcSEcCtD
Sirolimus—Hypotension—Methylprednisolone—multiple sclerosis	9.23e-05	0.000387	CcSEcCtD
Sirolimus—Pain—Prednisolone—multiple sclerosis	9.2e-05	0.000386	CcSEcCtD
Sirolimus—Haemorrhage—Methotrexate—multiple sclerosis	9.2e-05	0.000386	CcSEcCtD
Sirolimus—Pharyngitis—Methotrexate—multiple sclerosis	9.13e-05	0.000383	CcSEcCtD
Sirolimus—Urinary tract disorder—Methotrexate—multiple sclerosis	9.08e-05	0.000381	CcSEcCtD
Sirolimus—Urethral disorder—Methotrexate—multiple sclerosis	9.02e-05	0.000378	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	9.01e-05	0.000378	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	8.99e-05	0.000377	CcSEcCtD
Sirolimus—Anaphylactic shock—Betamethasone—multiple sclerosis	8.98e-05	0.000377	CcSEcCtD
Sirolimus—Anaphylactic shock—Dexamethasone—multiple sclerosis	8.98e-05	0.000377	CcSEcCtD
Sirolimus—Oedema—Betamethasone—multiple sclerosis	8.98e-05	0.000377	CcSEcCtD
Sirolimus—Oedema—Dexamethasone—multiple sclerosis	8.98e-05	0.000377	CcSEcCtD
Sirolimus—Diarrhoea—Mitoxantrone—multiple sclerosis	8.97e-05	0.000377	CcSEcCtD
Sirolimus—Insomnia—Triamcinolone—multiple sclerosis	8.95e-05	0.000376	CcSEcCtD
Sirolimus—Insomnia—Methylprednisolone—multiple sclerosis	8.93e-05	0.000375	CcSEcCtD
Sirolimus—Infection—Betamethasone—multiple sclerosis	8.92e-05	0.000374	CcSEcCtD
Sirolimus—Infection—Dexamethasone—multiple sclerosis	8.92e-05	0.000374	CcSEcCtD
Sirolimus—Ill-defined disorder—Prednisone—multiple sclerosis	8.89e-05	0.000373	CcSEcCtD
Sirolimus—Paraesthesia—Triamcinolone—multiple sclerosis	8.88e-05	0.000373	CcSEcCtD
Sirolimus—Feeling abnormal—Prednisolone—multiple sclerosis	8.87e-05	0.000372	CcSEcCtD
Sirolimus—Paraesthesia—Methylprednisolone—multiple sclerosis	8.86e-05	0.000372	CcSEcCtD
Sirolimus—Visual impairment—Methotrexate—multiple sclerosis	8.86e-05	0.000372	CcSEcCtD
Sirolimus—Anaemia—Prednisone—multiple sclerosis	8.85e-05	0.000372	CcSEcCtD
Sirolimus—Shock—Betamethasone—multiple sclerosis	8.83e-05	0.000371	CcSEcCtD
Sirolimus—Shock—Dexamethasone—multiple sclerosis	8.83e-05	0.000371	CcSEcCtD
Sirolimus—Dyspnoea—Triamcinolone—multiple sclerosis	8.82e-05	0.00037	CcSEcCtD
Sirolimus—Nervous system disorder—Dexamethasone—multiple sclerosis	8.8e-05	0.000369	CcSEcCtD
Sirolimus—Nervous system disorder—Betamethasone—multiple sclerosis	8.8e-05	0.000369	CcSEcCtD
Sirolimus—Agitation—Prednisone—multiple sclerosis	8.8e-05	0.000369	CcSEcCtD
Sirolimus—Thrombocytopenia—Dexamethasone—multiple sclerosis	8.79e-05	0.000369	CcSEcCtD
Sirolimus—Thrombocytopenia—Betamethasone—multiple sclerosis	8.79e-05	0.000369	CcSEcCtD
Sirolimus—Tachycardia—Dexamethasone—multiple sclerosis	8.76e-05	0.000368	CcSEcCtD
Sirolimus—Tachycardia—Betamethasone—multiple sclerosis	8.76e-05	0.000368	CcSEcCtD
Sirolimus—Angioedema—Prednisone—multiple sclerosis	8.75e-05	0.000367	CcSEcCtD
Sirolimus—Dyspepsia—Triamcinolone—multiple sclerosis	8.71e-05	0.000365	CcSEcCtD
Sirolimus—Dyspepsia—Methylprednisolone—multiple sclerosis	8.69e-05	0.000365	CcSEcCtD
Sirolimus—Hyperhidrosis—Betamethasone—multiple sclerosis	8.68e-05	0.000364	CcSEcCtD
Sirolimus—Hyperhidrosis—Dexamethasone—multiple sclerosis	8.68e-05	0.000364	CcSEcCtD
Sirolimus—Malaise—Prednisone—multiple sclerosis	8.64e-05	0.000362	CcSEcCtD
Sirolimus—Syncope—Prednisone—multiple sclerosis	8.59e-05	0.00036	CcSEcCtD
Sirolimus—Tinnitus—Methotrexate—multiple sclerosis	8.58e-05	0.00036	CcSEcCtD
Sirolimus—Anorexia—Dexamethasone—multiple sclerosis	8.56e-05	0.000359	CcSEcCtD
Sirolimus—Anorexia—Betamethasone—multiple sclerosis	8.56e-05	0.000359	CcSEcCtD
Sirolimus—Cardiac disorder—Methotrexate—multiple sclerosis	8.54e-05	0.000358	CcSEcCtD
Sirolimus—Pain—Triamcinolone—multiple sclerosis	8.46e-05	0.000355	CcSEcCtD
Sirolimus—Loss of consciousness—Prednisone—multiple sclerosis	8.42e-05	0.000353	CcSEcCtD
Sirolimus—Hypotension—Dexamethasone—multiple sclerosis	8.39e-05	0.000352	CcSEcCtD
Sirolimus—Hypotension—Betamethasone—multiple sclerosis	8.39e-05	0.000352	CcSEcCtD
Sirolimus—Angiopathy—Methotrexate—multiple sclerosis	8.34e-05	0.00035	CcSEcCtD
Sirolimus—Vomiting—Mitoxantrone—multiple sclerosis	8.34e-05	0.00035	CcSEcCtD
Sirolimus—Immune system disorder—Methotrexate—multiple sclerosis	8.31e-05	0.000349	CcSEcCtD
Sirolimus—Mediastinal disorder—Methotrexate—multiple sclerosis	8.29e-05	0.000348	CcSEcCtD
Sirolimus—Hypertension—Prednisone—multiple sclerosis	8.27e-05	0.000347	CcSEcCtD
Sirolimus—Rash—Mitoxantrone—multiple sclerosis	8.27e-05	0.000347	CcSEcCtD
Sirolimus—Dermatitis—Mitoxantrone—multiple sclerosis	8.26e-05	0.000347	CcSEcCtD
Sirolimus—Chills—Methotrexate—multiple sclerosis	8.25e-05	0.000346	CcSEcCtD
Sirolimus—Headache—Mitoxantrone—multiple sclerosis	8.22e-05	0.000345	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	8.18e-05	0.000343	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	8.18e-05	0.000343	CcSEcCtD
Sirolimus—Arthralgia—Prednisone—multiple sclerosis	8.16e-05	0.000342	CcSEcCtD
Sirolimus—Myalgia—Prednisone—multiple sclerosis	8.16e-05	0.000342	CcSEcCtD
Sirolimus—Feeling abnormal—Triamcinolone—multiple sclerosis	8.15e-05	0.000342	CcSEcCtD
Sirolimus—Feeling abnormal—Methylprednisolone—multiple sclerosis	8.14e-05	0.000341	CcSEcCtD
Sirolimus—Anxiety—Prednisone—multiple sclerosis	8.13e-05	0.000341	CcSEcCtD
Sirolimus—Insomnia—Dexamethasone—multiple sclerosis	8.12e-05	0.000341	CcSEcCtD
Sirolimus—Insomnia—Betamethasone—multiple sclerosis	8.12e-05	0.000341	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	8.1e-05	0.00034	CcSEcCtD
Sirolimus—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	8.07e-05	0.000339	CcSEcCtD
Sirolimus—Paraesthesia—Betamethasone—multiple sclerosis	8.06e-05	0.000338	CcSEcCtD
Sirolimus—Paraesthesia—Dexamethasone—multiple sclerosis	8.06e-05	0.000338	CcSEcCtD
Sirolimus—Discomfort—Prednisone—multiple sclerosis	8.06e-05	0.000338	CcSEcCtD
Sirolimus—Malnutrition—Methotrexate—multiple sclerosis	8.01e-05	0.000336	CcSEcCtD
Sirolimus—Hypersensitivity—Prednisolone—multiple sclerosis	7.93e-05	0.000333	CcSEcCtD
Sirolimus—Dyspepsia—Betamethasone—multiple sclerosis	7.9e-05	0.000332	CcSEcCtD
Sirolimus—Dyspepsia—Dexamethasone—multiple sclerosis	7.9e-05	0.000332	CcSEcCtD
Sirolimus—Body temperature increased—Triamcinolone—multiple sclerosis	7.82e-05	0.000328	CcSEcCtD
Sirolimus—Anaphylactic shock—Prednisone—multiple sclerosis	7.82e-05	0.000328	CcSEcCtD
Sirolimus—Oedema—Prednisone—multiple sclerosis	7.82e-05	0.000328	CcSEcCtD
Sirolimus—Abdominal pain—Methylprednisolone—multiple sclerosis	7.8e-05	0.000327	CcSEcCtD
Sirolimus—Decreased appetite—Betamethasone—multiple sclerosis	7.8e-05	0.000327	CcSEcCtD
Sirolimus—Decreased appetite—Dexamethasone—multiple sclerosis	7.8e-05	0.000327	CcSEcCtD
Sirolimus—Nausea—Mitoxantrone—multiple sclerosis	7.79e-05	0.000327	CcSEcCtD
Sirolimus—Infection—Prednisone—multiple sclerosis	7.77e-05	0.000326	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	7.75e-05	0.000325	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Betamethasone—multiple sclerosis	7.75e-05	0.000325	CcSEcCtD
Sirolimus—Back pain—Methotrexate—multiple sclerosis	7.74e-05	0.000325	CcSEcCtD
Sirolimus—Shock—Prednisone—multiple sclerosis	7.69e-05	0.000323	CcSEcCtD
Sirolimus—Pain—Dexamethasone—multiple sclerosis	7.68e-05	0.000322	CcSEcCtD
Sirolimus—Pain—Betamethasone—multiple sclerosis	7.68e-05	0.000322	CcSEcCtD
Sirolimus—Nervous system disorder—Prednisone—multiple sclerosis	7.67e-05	0.000322	CcSEcCtD
Sirolimus—Tachycardia—Prednisone—multiple sclerosis	7.63e-05	0.00032	CcSEcCtD
Sirolimus—Skin disorder—Prednisone—multiple sclerosis	7.59e-05	0.000319	CcSEcCtD
Sirolimus—Hyperhidrosis—Prednisone—multiple sclerosis	7.56e-05	0.000317	CcSEcCtD
Sirolimus—Anorexia—Prednisone—multiple sclerosis	7.45e-05	0.000313	CcSEcCtD
Sirolimus—Ill-defined disorder—Methotrexate—multiple sclerosis	7.43e-05	0.000312	CcSEcCtD
Sirolimus—Anaemia—Methotrexate—multiple sclerosis	7.4e-05	0.000311	CcSEcCtD
Sirolimus—Feeling abnormal—Betamethasone—multiple sclerosis	7.4e-05	0.00031	CcSEcCtD
Sirolimus—Feeling abnormal—Dexamethasone—multiple sclerosis	7.4e-05	0.00031	CcSEcCtD
Sirolimus—Gastrointestinal pain—Dexamethasone—multiple sclerosis	7.34e-05	0.000308	CcSEcCtD
Sirolimus—Gastrointestinal pain—Betamethasone—multiple sclerosis	7.34e-05	0.000308	CcSEcCtD
Sirolimus—Hypersensitivity—Triamcinolone—multiple sclerosis	7.29e-05	0.000306	CcSEcCtD
Sirolimus—Hypersensitivity—Methylprednisolone—multiple sclerosis	7.27e-05	0.000305	CcSEcCtD
Sirolimus—Malaise—Methotrexate—multiple sclerosis	7.22e-05	0.000303	CcSEcCtD
Sirolimus—Leukopenia—Methotrexate—multiple sclerosis	7.17e-05	0.000301	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Prednisone—multiple sclerosis	7.12e-05	0.000299	CcSEcCtD
Sirolimus—Dizziness—Prednisolone—multiple sclerosis	7.11e-05	0.000299	CcSEcCtD
Sirolimus—Asthenia—Triamcinolone—multiple sclerosis	7.1e-05	0.000298	CcSEcCtD
Sirolimus—Abdominal pain—Betamethasone—multiple sclerosis	7.1e-05	0.000298	CcSEcCtD
Sirolimus—Abdominal pain—Dexamethasone—multiple sclerosis	7.1e-05	0.000298	CcSEcCtD
Sirolimus—Body temperature increased—Betamethasone—multiple sclerosis	7.1e-05	0.000298	CcSEcCtD
Sirolimus—Body temperature increased—Dexamethasone—multiple sclerosis	7.1e-05	0.000298	CcSEcCtD
Sirolimus—Asthenia—Methylprednisolone—multiple sclerosis	7.08e-05	0.000297	CcSEcCtD
Sirolimus—Insomnia—Prednisone—multiple sclerosis	7.07e-05	0.000297	CcSEcCtD
Sirolimus—Paraesthesia—Prednisone—multiple sclerosis	7.02e-05	0.000295	CcSEcCtD
Sirolimus—Pruritus—Triamcinolone—multiple sclerosis	7e-05	0.000294	CcSEcCtD
Sirolimus—Cough—Methotrexate—multiple sclerosis	6.99e-05	0.000293	CcSEcCtD
Sirolimus—Pruritus—Methylprednisolone—multiple sclerosis	6.98e-05	0.000293	CcSEcCtD
Sirolimus—Dyspepsia—Prednisone—multiple sclerosis	6.88e-05	0.000289	CcSEcCtD
Sirolimus—Myalgia—Methotrexate—multiple sclerosis	6.82e-05	0.000286	CcSEcCtD
Sirolimus—Arthralgia—Methotrexate—multiple sclerosis	6.82e-05	0.000286	CcSEcCtD
Sirolimus—Chest pain—Methotrexate—multiple sclerosis	6.82e-05	0.000286	CcSEcCtD
Sirolimus—Decreased appetite—Prednisone—multiple sclerosis	6.8e-05	0.000285	CcSEcCtD
Sirolimus—Rash—Prednisolone—multiple sclerosis	6.78e-05	0.000285	CcSEcCtD
Sirolimus—Dermatitis—Prednisolone—multiple sclerosis	6.78e-05	0.000284	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	6.77e-05	0.000284	CcSEcCtD
Sirolimus—Diarrhoea—Methylprednisolone—multiple sclerosis	6.75e-05	0.000283	CcSEcCtD
Sirolimus—Headache—Prednisolone—multiple sclerosis	6.74e-05	0.000283	CcSEcCtD
Sirolimus—Discomfort—Methotrexate—multiple sclerosis	6.73e-05	0.000283	CcSEcCtD
Sirolimus—Constipation—Prednisone—multiple sclerosis	6.69e-05	0.000281	CcSEcCtD
Sirolimus—Confusional state—Methotrexate—multiple sclerosis	6.59e-05	0.000276	CcSEcCtD
Sirolimus—Dizziness—Triamcinolone—multiple sclerosis	6.54e-05	0.000275	CcSEcCtD
Sirolimus—Anaphylactic shock—Methotrexate—multiple sclerosis	6.53e-05	0.000274	CcSEcCtD
Sirolimus—Dizziness—Methylprednisolone—multiple sclerosis	6.53e-05	0.000274	CcSEcCtD
Sirolimus—Infection—Methotrexate—multiple sclerosis	6.49e-05	0.000272	CcSEcCtD
Sirolimus—Feeling abnormal—Prednisone—multiple sclerosis	6.44e-05	0.00027	CcSEcCtD
Sirolimus—Asthenia—Dexamethasone—multiple sclerosis	6.44e-05	0.00027	CcSEcCtD
Sirolimus—Asthenia—Betamethasone—multiple sclerosis	6.44e-05	0.00027	CcSEcCtD
Sirolimus—Nervous system disorder—Methotrexate—multiple sclerosis	6.41e-05	0.000269	CcSEcCtD
Sirolimus—Thrombocytopenia—Methotrexate—multiple sclerosis	6.4e-05	0.000268	CcSEcCtD
Sirolimus—Gastrointestinal pain—Prednisone—multiple sclerosis	6.39e-05	0.000268	CcSEcCtD
Sirolimus—Nausea—Prednisolone—multiple sclerosis	6.39e-05	0.000268	CcSEcCtD
Sirolimus—Pruritus—Betamethasone—multiple sclerosis	6.35e-05	0.000267	CcSEcCtD
Sirolimus—Pruritus—Dexamethasone—multiple sclerosis	6.35e-05	0.000267	CcSEcCtD
Sirolimus—Skin disorder—Methotrexate—multiple sclerosis	6.35e-05	0.000266	CcSEcCtD
Sirolimus—Hyperhidrosis—Methotrexate—multiple sclerosis	6.32e-05	0.000265	CcSEcCtD
Sirolimus—Vomiting—Triamcinolone—multiple sclerosis	6.29e-05	0.000264	CcSEcCtD
Sirolimus—Vomiting—Methylprednisolone—multiple sclerosis	6.28e-05	0.000263	CcSEcCtD
Sirolimus—Rash—Triamcinolone—multiple sclerosis	6.24e-05	0.000262	CcSEcCtD
Sirolimus—Dermatitis—Triamcinolone—multiple sclerosis	6.23e-05	0.000262	CcSEcCtD
Sirolimus—Anorexia—Methotrexate—multiple sclerosis	6.23e-05	0.000261	CcSEcCtD
Sirolimus—Rash—Methylprednisolone—multiple sclerosis	6.22e-05	0.000261	CcSEcCtD
Sirolimus—Dermatitis—Methylprednisolone—multiple sclerosis	6.22e-05	0.000261	CcSEcCtD
Sirolimus—Headache—Triamcinolone—multiple sclerosis	6.2e-05	0.00026	CcSEcCtD
Sirolimus—Headache—Methylprednisolone—multiple sclerosis	6.18e-05	0.00026	CcSEcCtD
Sirolimus—Abdominal pain—Prednisone—multiple sclerosis	6.18e-05	0.000259	CcSEcCtD
Sirolimus—Body temperature increased—Prednisone—multiple sclerosis	6.18e-05	0.000259	CcSEcCtD
Sirolimus—Diarrhoea—Dexamethasone—multiple sclerosis	6.14e-05	0.000258	CcSEcCtD
Sirolimus—Diarrhoea—Betamethasone—multiple sclerosis	6.14e-05	0.000258	CcSEcCtD
Sirolimus—Hypotension—Methotrexate—multiple sclerosis	6.11e-05	0.000256	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	5.95e-05	0.00025	CcSEcCtD
Sirolimus—Dizziness—Dexamethasone—multiple sclerosis	5.94e-05	0.000249	CcSEcCtD
Sirolimus—Dizziness—Betamethasone—multiple sclerosis	5.94e-05	0.000249	CcSEcCtD
Sirolimus—Insomnia—Methotrexate—multiple sclerosis	5.91e-05	0.000248	CcSEcCtD
Sirolimus—Nausea—Triamcinolone—multiple sclerosis	5.88e-05	0.000247	CcSEcCtD
Sirolimus—Paraesthesia—Methotrexate—multiple sclerosis	5.87e-05	0.000246	CcSEcCtD
Sirolimus—Nausea—Methylprednisolone—multiple sclerosis	5.86e-05	0.000246	CcSEcCtD
Sirolimus—Dyspnoea—Methotrexate—multiple sclerosis	5.83e-05	0.000244	CcSEcCtD
Sirolimus—Somnolence—Methotrexate—multiple sclerosis	5.81e-05	0.000244	CcSEcCtD
Sirolimus—Hypersensitivity—Prednisone—multiple sclerosis	5.76e-05	0.000242	CcSEcCtD
Sirolimus—Dyspepsia—Methotrexate—multiple sclerosis	5.75e-05	0.000241	CcSEcCtD
Sirolimus—Vomiting—Dexamethasone—multiple sclerosis	5.71e-05	0.00024	CcSEcCtD
Sirolimus—Vomiting—Betamethasone—multiple sclerosis	5.71e-05	0.00024	CcSEcCtD
Sirolimus—Decreased appetite—Methotrexate—multiple sclerosis	5.68e-05	0.000238	CcSEcCtD
Sirolimus—Rash—Dexamethasone—multiple sclerosis	5.66e-05	0.000238	CcSEcCtD
Sirolimus—Rash—Betamethasone—multiple sclerosis	5.66e-05	0.000238	CcSEcCtD
Sirolimus—Dermatitis—Dexamethasone—multiple sclerosis	5.66e-05	0.000237	CcSEcCtD
Sirolimus—Dermatitis—Betamethasone—multiple sclerosis	5.66e-05	0.000237	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Methotrexate—multiple sclerosis	5.64e-05	0.000237	CcSEcCtD
Sirolimus—Headache—Betamethasone—multiple sclerosis	5.62e-05	0.000236	CcSEcCtD
Sirolimus—Headache—Dexamethasone—multiple sclerosis	5.62e-05	0.000236	CcSEcCtD
Sirolimus—Asthenia—Prednisone—multiple sclerosis	5.61e-05	0.000235	CcSEcCtD
Sirolimus—Pain—Methotrexate—multiple sclerosis	5.59e-05	0.000234	CcSEcCtD
Sirolimus—Pruritus—Prednisone—multiple sclerosis	5.53e-05	0.000232	CcSEcCtD
Sirolimus—Feeling abnormal—Methotrexate—multiple sclerosis	5.38e-05	0.000226	CcSEcCtD
Sirolimus—Diarrhoea—Prednisone—multiple sclerosis	5.35e-05	0.000224	CcSEcCtD
Sirolimus—Gastrointestinal pain—Methotrexate—multiple sclerosis	5.34e-05	0.000224	CcSEcCtD
Sirolimus—Nausea—Dexamethasone—multiple sclerosis	5.33e-05	0.000224	CcSEcCtD
Sirolimus—Nausea—Betamethasone—multiple sclerosis	5.33e-05	0.000224	CcSEcCtD
Sirolimus—Dizziness—Prednisone—multiple sclerosis	5.17e-05	0.000217	CcSEcCtD
Sirolimus—Body temperature increased—Methotrexate—multiple sclerosis	5.17e-05	0.000217	CcSEcCtD
Sirolimus—Abdominal pain—Methotrexate—multiple sclerosis	5.17e-05	0.000217	CcSEcCtD
Sirolimus—Vomiting—Prednisone—multiple sclerosis	4.97e-05	0.000209	CcSEcCtD
Sirolimus—Rash—Prednisone—multiple sclerosis	4.93e-05	0.000207	CcSEcCtD
Sirolimus—Dermatitis—Prednisone—multiple sclerosis	4.93e-05	0.000207	CcSEcCtD
Sirolimus—Headache—Prednisone—multiple sclerosis	4.9e-05	0.000206	CcSEcCtD
Sirolimus—Hypersensitivity—Methotrexate—multiple sclerosis	4.81e-05	0.000202	CcSEcCtD
Sirolimus—Asthenia—Methotrexate—multiple sclerosis	4.69e-05	0.000197	CcSEcCtD
Sirolimus—Nausea—Prednisone—multiple sclerosis	4.64e-05	0.000195	CcSEcCtD
Sirolimus—Pruritus—Methotrexate—multiple sclerosis	4.62e-05	0.000194	CcSEcCtD
Sirolimus—Diarrhoea—Methotrexate—multiple sclerosis	4.47e-05	0.000188	CcSEcCtD
Sirolimus—Dizziness—Methotrexate—multiple sclerosis	4.32e-05	0.000181	CcSEcCtD
Sirolimus—Vomiting—Methotrexate—multiple sclerosis	4.15e-05	0.000174	CcSEcCtD
Sirolimus—Rash—Methotrexate—multiple sclerosis	4.12e-05	0.000173	CcSEcCtD
Sirolimus—Dermatitis—Methotrexate—multiple sclerosis	4.12e-05	0.000173	CcSEcCtD
Sirolimus—Headache—Methotrexate—multiple sclerosis	4.09e-05	0.000172	CcSEcCtD
Sirolimus—Nausea—Methotrexate—multiple sclerosis	3.88e-05	0.000163	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—CCR5—multiple sclerosis	2.91e-05	0.000173	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—STAT3—multiple sclerosis	2.89e-05	0.000172	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL13—multiple sclerosis	2.89e-05	0.000172	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCR1—multiple sclerosis	2.89e-05	0.000172	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CCR2—multiple sclerosis	2.88e-05	0.000171	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PTPRC—multiple sclerosis	2.88e-05	0.000171	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL2RA—multiple sclerosis	2.87e-05	0.000171	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	2.84e-05	0.000169	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	2.84e-05	0.000169	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—TLR4—multiple sclerosis	2.84e-05	0.000169	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—TNF—multiple sclerosis	2.83e-05	0.000169	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD4—multiple sclerosis	2.82e-05	0.000168	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD86—multiple sclerosis	2.82e-05	0.000168	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—IL6—multiple sclerosis	2.78e-05	0.000166	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—multiple sclerosis	2.78e-05	0.000166	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—IL6—multiple sclerosis	2.78e-05	0.000166	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-DPB1—multiple sclerosis	2.78e-05	0.000166	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCL3—multiple sclerosis	2.77e-05	0.000165	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—APOE—multiple sclerosis	2.77e-05	0.000165	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD40LG—multiple sclerosis	2.76e-05	0.000165	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—IL6—multiple sclerosis	2.76e-05	0.000164	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CXCL10—multiple sclerosis	2.75e-05	0.000164	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—IL6—multiple sclerosis	2.73e-05	0.000163	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD8A—multiple sclerosis	2.73e-05	0.000163	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HLA-DRB1—multiple sclerosis	2.72e-05	0.000162	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—IL6—multiple sclerosis	2.72e-05	0.000162	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—STAT3—multiple sclerosis	2.72e-05	0.000162	CbGpPWpGaD
Sirolimus—MTOR—Disease—CD28—multiple sclerosis	2.71e-05	0.000161	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CD4—multiple sclerosis	2.7e-05	0.000161	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ITGA4—multiple sclerosis	2.68e-05	0.000159	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD40—multiple sclerosis	2.68e-05	0.000159	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTGER4—multiple sclerosis	2.67e-05	0.000159	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—MMP9—multiple sclerosis	2.66e-05	0.000158	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IFNB1—multiple sclerosis	2.66e-05	0.000158	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—APOE—multiple sclerosis	2.65e-05	0.000158	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CTLA4—multiple sclerosis	2.64e-05	0.000157	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—MAPK1—multiple sclerosis	2.63e-05	0.000157	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HLA-B—multiple sclerosis	2.63e-05	0.000157	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PGR—multiple sclerosis	2.63e-05	0.000157	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CD80—multiple sclerosis	2.62e-05	0.000156	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—ICAM1—multiple sclerosis	2.61e-05	0.000156	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.61e-05	0.000155	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL1B—multiple sclerosis	2.61e-05	0.000155	CbGpPWpGaD
Sirolimus—FGF2—Disease—CD86—multiple sclerosis	2.6e-05	0.000155	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GPC5—multiple sclerosis	2.6e-05	0.000155	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL2—multiple sclerosis	2.6e-05	0.000155	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD4—multiple sclerosis	2.59e-05	0.000154	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCR3—multiple sclerosis	2.58e-05	0.000154	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—IL6—multiple sclerosis	2.56e-05	0.000152	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CD28—multiple sclerosis	2.55e-05	0.000152	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.52e-05	0.00015	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD80—multiple sclerosis	2.52e-05	0.00015	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCR2—multiple sclerosis	2.51e-05	0.000149	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CD80—multiple sclerosis	2.51e-05	0.000149	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—MAPK1—multiple sclerosis	2.47e-05	0.000147	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	2.47e-05	0.000147	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL2RA—multiple sclerosis	2.46e-05	0.000147	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HLA-A—multiple sclerosis	2.44e-05	0.000145	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CD86—multiple sclerosis	2.4e-05	0.000143	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CD80—multiple sclerosis	2.39e-05	0.000142	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCL5—multiple sclerosis	2.37e-05	0.000141	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—STAT3—multiple sclerosis	2.36e-05	0.000141	CbGpPWpGaD
Sirolimus—MTOR—Immune System—VCAM1—multiple sclerosis	2.33e-05	0.000139	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-DQA1—multiple sclerosis	2.32e-05	0.000138	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CNR1—multiple sclerosis	2.31e-05	0.000138	CbGpPWpGaD
Sirolimus—FGF2—Disease—CCR5—multiple sclerosis	2.31e-05	0.000137	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—POMC—multiple sclerosis	2.27e-05	0.000135	CbGpPWpGaD
Sirolimus—FGF2—Disease—HLA-A—multiple sclerosis	2.25e-05	0.000134	CbGpPWpGaD
Sirolimus—FGF2—Immune System—TLR4—multiple sclerosis	2.23e-05	0.000133	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HLA-DRB1—multiple sclerosis	2.23e-05	0.000133	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCL2—multiple sclerosis	2.22e-05	0.000132	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—TYK2—multiple sclerosis	2.21e-05	0.000132	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SPP1—multiple sclerosis	2.19e-05	0.000131	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TGFB1—multiple sclerosis	2.19e-05	0.00013	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—STAT3—multiple sclerosis	2.19e-05	0.00013	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-DQB1—multiple sclerosis	2.17e-05	0.000129	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.16e-05	0.000129	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—RRM1—multiple sclerosis	2.15e-05	0.000128	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—MAPK1—multiple sclerosis	2.15e-05	0.000128	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP27B1—multiple sclerosis	2.15e-05	0.000128	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP24A1—multiple sclerosis	2.15e-05	0.000128	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ICAM1—multiple sclerosis	2.14e-05	0.000127	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCR5—multiple sclerosis	2.13e-05	0.000127	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TYK2—multiple sclerosis	2.11e-05	0.000126	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL2RA—multiple sclerosis	2.1e-05	0.000125	CbGpPWpGaD
Sirolimus—FGF2—Disease—APOE—multiple sclerosis	2.1e-05	0.000125	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD86—multiple sclerosis	2.09e-05	0.000125	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCL10—multiple sclerosis	2.08e-05	0.000124	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCL3—multiple sclerosis	2.06e-05	0.000123	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD80—multiple sclerosis	2.06e-05	0.000122	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD40LG—multiple sclerosis	2.05e-05	0.000122	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TNF—multiple sclerosis	2.05e-05	0.000122	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD8A—multiple sclerosis	2.03e-05	0.000121	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—IL6—multiple sclerosis	2.02e-05	0.00012	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—MYC—multiple sclerosis	2.02e-05	0.00012	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TYK2—multiple sclerosis	2.02e-05	0.00012	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CD4—multiple sclerosis	2e-05	0.000119	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—MAPK1—multiple sclerosis	1.99e-05	0.000118	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTGER4—multiple sclerosis	1.98e-05	0.000118	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.97e-05	0.000118	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GPC5—multiple sclerosis	1.96e-05	0.000117	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-B—multiple sclerosis	1.95e-05	0.000116	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PGR—multiple sclerosis	1.95e-05	0.000116	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—APOE—multiple sclerosis	1.94e-05	0.000116	CbGpPWpGaD
Sirolimus—MTOR—Disease—CD86—multiple sclerosis	1.93e-05	0.000115	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD4—multiple sclerosis	1.92e-05	0.000114	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCR3—multiple sclerosis	1.91e-05	0.000114	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CD4—multiple sclerosis	1.91e-05	0.000114	CbGpPWpGaD
Sirolimus—FGF2—Disease—CD80—multiple sclerosis	1.9e-05	0.000113	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—MAPK1—multiple sclerosis	1.9e-05	0.000113	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—IL6—multiple sclerosis	1.9e-05	0.000113	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CD28—multiple sclerosis	1.9e-05	0.000113	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.88e-05	0.000112	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SRM—multiple sclerosis	1.88e-05	0.000112	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—BCHE—multiple sclerosis	1.87e-05	0.000111	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCR2—multiple sclerosis	1.86e-05	0.000111	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2RA—multiple sclerosis	1.83e-05	0.000109	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CD86—multiple sclerosis	1.82e-05	0.000109	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-A—multiple sclerosis	1.81e-05	0.000108	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCL5—multiple sclerosis	1.79e-05	0.000107	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CD80—multiple sclerosis	1.75e-05	0.000104	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.74e-05	0.000104	CbGpPWpGaD
Sirolimus—FGF2—Immune System—TYK2—multiple sclerosis	1.74e-05	0.000103	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CNR1—multiple sclerosis	1.72e-05	0.000102	CbGpPWpGaD
Sirolimus—MTOR—Disease—CCR5—multiple sclerosis	1.71e-05	0.000102	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—BCHE—multiple sclerosis	1.71e-05	0.000102	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL2—multiple sclerosis	1.68e-05	0.0001	CbGpPWpGaD
Sirolimus—MTOR—Disease—HLA-A—multiple sclerosis	1.67e-05	9.94e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—POMC—multiple sclerosis	1.67e-05	9.93e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SPP1—multiple sclerosis	1.66e-05	9.9e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—TLR4—multiple sclerosis	1.65e-05	9.85e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-DRB1—multiple sclerosis	1.65e-05	9.84e-05	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—IL6—multiple sclerosis	1.65e-05	9.83e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCL2—multiple sclerosis	1.63e-05	9.71e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—RRM1—multiple sclerosis	1.63e-05	9.68e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IFNG—multiple sclerosis	1.63e-05	9.68e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCR5—multiple sclerosis	1.62e-05	9.63e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—TYK2—multiple sclerosis	1.6e-05	9.55e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2RA—multiple sclerosis	1.59e-05	9.49e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MMP9—multiple sclerosis	1.59e-05	9.47e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ICAM1—multiple sclerosis	1.59e-05	9.44e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD4—multiple sclerosis	1.57e-05	9.35e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—APOE—multiple sclerosis	1.56e-05	9.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL10—multiple sclerosis	1.55e-05	9.21e-05	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL6—multiple sclerosis	1.53e-05	9.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD80—multiple sclerosis	1.53e-05	9.09e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.5e-05	8.94e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.5e-05	8.91e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TYK2—multiple sclerosis	1.48e-05	8.82e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—STAT3—multiple sclerosis	1.48e-05	8.82e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—APOE—multiple sclerosis	1.47e-05	8.76e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.47e-05	8.74e-05	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—IL6—multiple sclerosis	1.46e-05	8.68e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL1B—multiple sclerosis	1.45e-05	8.64e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—CD4—multiple sclerosis	1.45e-05	8.63e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL2—multiple sclerosis	1.44e-05	8.6e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—STAT3—multiple sclerosis	1.41e-05	8.42e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CD80—multiple sclerosis	1.41e-05	8.39e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MAPK1—multiple sclerosis	1.41e-05	8.39e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.4e-05	8.32e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MYC—multiple sclerosis	1.38e-05	8.2e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TGFB1—multiple sclerosis	1.37e-05	8.18e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CD86—multiple sclerosis	1.35e-05	8.06e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MAPK1—multiple sclerosis	1.35e-05	8.02e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCL5—multiple sclerosis	1.33e-05	7.93e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CD80—multiple sclerosis	1.33e-05	7.92e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.32e-05	7.87e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.32e-05	7.87e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—multiple sclerosis	1.31e-05	7.82e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TGFB1—multiple sclerosis	1.31e-05	7.81e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—TYK2—multiple sclerosis	1.29e-05	7.67e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MAPK1—multiple sclerosis	1.29e-05	7.65e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—POMC—multiple sclerosis	1.26e-05	7.52e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.24e-05	7.37e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCL2—multiple sclerosis	1.24e-05	7.36e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SPP1—multiple sclerosis	1.23e-05	7.34e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL2—multiple sclerosis	1.23e-05	7.34e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—STAT3—multiple sclerosis	1.22e-05	7.24e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.21e-05	7.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IFNG—multiple sclerosis	1.21e-05	7.18e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCR5—multiple sclerosis	1.2e-05	7.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—TYK2—multiple sclerosis	1.19e-05	7.08e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2RA—multiple sclerosis	1.18e-05	7.04e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—multiple sclerosis	1.17e-05	6.95e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD4—multiple sclerosis	1.17e-05	6.94e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TYK2—multiple sclerosis	1.12e-05	6.68e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—APOE—multiple sclerosis	1.12e-05	6.68e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—STAT3—multiple sclerosis	1.12e-05	6.68e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MAPK1—multiple sclerosis	1.1e-05	6.58e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APOE—multiple sclerosis	1.09e-05	6.5e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—multiple sclerosis	1.08e-05	6.44e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL1B—multiple sclerosis	1.08e-05	6.41e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CD4—multiple sclerosis	1.08e-05	6.41e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2—multiple sclerosis	1.07e-05	6.38e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—multiple sclerosis	1.04e-05	6.21e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFB1—multiple sclerosis	1.04e-05	6.2e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STAT3—multiple sclerosis	1.04e-05	6.18e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—multiple sclerosis	1.03e-05	6.16e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—APOE—multiple sclerosis	1.03e-05	6.13e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MAPK1—multiple sclerosis	1.02e-05	6.08e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—RRM1—multiple sclerosis	1e-05	5.97e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—multiple sclerosis	9.87e-06	5.88e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CD80—multiple sclerosis	9.87e-06	5.88e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—POMC—multiple sclerosis	9.64e-06	5.74e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—multiple sclerosis	9.64e-06	5.74e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TGFB1—multiple sclerosis	9.61e-06	5.73e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK1—multiple sclerosis	9.43e-06	5.61e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.4e-06	5.6e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—POMC—multiple sclerosis	9.37e-06	5.58e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—BCHE—multiple sclerosis	9.34e-06	5.56e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2—multiple sclerosis	9.34e-06	5.56e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCL2—multiple sclerosis	9.17e-06	5.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—STAT3—multiple sclerosis	9.02e-06	5.37e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—POMC—multiple sclerosis	8.85e-06	5.27e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—multiple sclerosis	8.84e-06	5.26e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ALB—multiple sclerosis	8.79e-06	5.24e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—multiple sclerosis	8.49e-06	5.06e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TYK2—multiple sclerosis	8.33e-06	4.96e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—STAT3—multiple sclerosis	8.33e-06	4.96e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK1—multiple sclerosis	8.2e-06	4.88e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ALB—multiple sclerosis	8.07e-06	4.8e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—STAT3—multiple sclerosis	7.86e-06	4.68e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—multiple sclerosis	7.84e-06	4.67e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—multiple sclerosis	7.74e-06	4.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—TGFB1—multiple sclerosis	7.72e-06	4.6e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MAPK1—multiple sclerosis	7.57e-06	4.51e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—APOE—multiple sclerosis	7.45e-06	4.43e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—multiple sclerosis	7.3e-06	4.35e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFB1—multiple sclerosis	7.28e-06	4.34e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—multiple sclerosis	7.24e-06	4.31e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK1—multiple sclerosis	7.14e-06	4.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2—multiple sclerosis	6.93e-06	4.13e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—multiple sclerosis	6.56e-06	3.91e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—POMC—multiple sclerosis	6.4e-06	3.81e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—multiple sclerosis	6.3e-06	3.75e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STAT3—multiple sclerosis	5.83e-06	3.47e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALB—multiple sclerosis	5.83e-06	3.47e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—multiple sclerosis	5.82e-06	3.46e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—BCHE—multiple sclerosis	5.75e-06	3.43e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—APOE—multiple sclerosis	5.62e-06	3.35e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—multiple sclerosis	5.49e-06	3.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—multiple sclerosis	5.42e-06	3.23e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFB1—multiple sclerosis	5.41e-06	3.22e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK1—multiple sclerosis	5.3e-06	3.16e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—POMC—multiple sclerosis	4.83e-06	2.87e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALB—multiple sclerosis	4.4e-06	2.62e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—multiple sclerosis	4.07e-06	2.43e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—APOE—multiple sclerosis	3.46e-06	2.06e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—POMC—multiple sclerosis	2.97e-06	1.77e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALB—multiple sclerosis	2.71e-06	1.61e-05	CbGpPWpGaD
